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Summary
Background LDL cholesterol has a causal role in the development of cardiovascular disease. Improved understanding 
of the biological mechanisms that underlie the metabolism and regulation of LDL cholesterol might help to identify 
novel therapeutic targets. We therefore did a genome-wide association study of LDL-cholesterol concentrations.
Methods We used genome-wide association data from up to 11 685 participants with measures of circulating 
LDL-cholesterol concentrations across ﬁ ve studies, including data for 293 461 autosomal single nucleotide 
polymorphisms (SNPs) with a minor allele frequency of 5% or more that passed our quality control criteria. We also 
used data from a second genome-wide array in up to 4337 participants from three of these ﬁ ve studies, with data for 
290 140 SNPs. We did replication studies in two independent populations consisting of up to 4979 participants. 
Statistical approaches, including meta-analysis and linkage disequilibrium plots, were used to reﬁ ne association 
signals; we analysed pooled data from all seven populations to determine the eﬀ ect of each SNP on variations in 
circulating LDL-cholesterol concentrations.
Findings In our initial scan, we found two SNPs (rs599839 [p=1·7×10–¹⁵] and rs4970834 [p=3·0×10–¹¹]) that showed 
genome-wide statistical association with LDL cholesterol at chromosomal locus 1p13.3. The second genome screen 
found a third statistically associated SNP at the same locus (rs646776 [p=4·3×10–⁹]). Meta-analysis of data from all 
studies showed an association of SNPs rs599839 (combined p=1·2×10–³³) and rs646776 (p=4·8×10–²⁰) with 
LDL-cholesterol concentrations. SNPs rs599839 and rs646776 both explained around 1% of the variation in circulating 
LDL-cholesterol concentrations and were associated with about 15% of an SD change in LDL cholesterol per allele, 
assuming an SD of 1 mmol/L.
Interpretation We found evidence for a novel locus for LDL cholesterol on chromosome 1p13.3. These results 
potentially provide insight into the biological mechanisms that underlie the regulation of LDL cholesterol and might 
help in the discovery of novel therapeutic targets for cardiovascular disease.
Introduction
LDL cholesterol has a causal role in the development of 
cardiovascular disease. Indeed, experimental studies 
have shown the clinical eﬃ  cacy of lowering concentrations 
of LDL cholesterol.1 Thus, regulation of LDL cholesterol 
represents a fundamental target for devising additional 
interventional strategies to reduce the risk of 
cardiovascular disease. In this context, understanding 
the biological mechanisms that underlie metabolism and 
regulation of LDL cholesterol might help to identify novel 
therapeutic targets.
Variation in LDL-cholesterol concentrations is a polygenic 
trait.2–4 Integration of genome-wide technologies and 
epidemiological approaches could help to identify novel 
genetic determinants of variation in LDL-cholesterol 
concentrations, providing new insights into the metabolism 
and regulation of LDL cholesterol.5,6 We therefore did a 
genome-wide association study on 11 685 participants with 
measures of circulating LDL-cholesterol concentrations 
across ﬁ ve studies. To validate these associations, we also 
did replication studies in independent populations.
Methods 
Participants
Data were gathered from ﬁ ve groups of individuals: two 
subcohorts of the EPIC-Norfolk study, the 1958 British 
birth cohort, the CoLaus study, and the Genetic 
Epidemiology of Metabolic Syndrome study.
The EPIC-Norfolk study is a population-based cohort 
study of 25 663 white European men and women aged 
39–79 years recruited in Norfolk, UK, between 1993 
and 1997.7 We examined a subcohort that consisted of 
2566 individuals who were randomly selected from the 
total cohort using a random selection algorithm. Serum 
total cholesterol, HDL cholesterol, and triglycerides were 
measured in fresh samples with the RA-1000 analyser 
(Bayer Diagnostics, Basingstoke, UK). LDL-cholesterol 
concentrations were calculated with the Friedewald 
formula.8 The Norwich local research ethics committee 
granted ethical approval for the study. All participants 
gave written informed consent.
The EPIC-Norfolk obese set is a case series also 
derived from the EPIC-Norfolk cohort, consisting of 
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1685 indi viduals with obesity (body-mass index [BMI] 
≥30 kg/m²). These cases were selected independently from 
the EPIC-Norfolk subcohort. Of these, 1284 cases were 
non-overlapping and used as a further study set. Serum 
total cholesterol, HDL cholesterol, and triglycerides were 
measured in fresh samples with the RA-1000 analyser, and 
LDL-cholesterol concentrations were calculated with the 
Friedewald formula.8 The Norwich local research ethics 
committee granted ethical approval for the study. All 
participants gave written informed consent.
The third study was the 1958 British birth cohort, a 
national population sample followed up periodically from 
birth to age 44–45 years, when a DNA bank was established 
as a national reference series for case-control studies.9 A 
geographically representative subsample of 1480 
participants who were selected as controls for the 
Wellcome Trust Case-Control Consortium genome-wide-
association studies10 were included in this analysis. 
Triglycerides, serum total cholesterol, and HDL cholesterol 
were measured in non-fasting serum with the Olympus 
model AU640 autoanalyser (Olympus Inc, Center Valley, 
PA, USA) by a clinical biochemistry laboratory. The 
concentration of LDL cholesterol was derived by the 
Friedewald formula.8 All participants included in this 
analysis gave written informed consent for the use of 
their DNA for non-commercial medical research 
purposes. Field protocols, informed consent, and this 
within-cohort genetic association analysis were approved 
by the South East NHS Multi-Centre Research Ethics 
Committee. 
Participants in the CoLaus (Cohorte Lausannoise) study 
were randomly selected from 56 694 individuals aged 
35–75 years who were permanent residents of Lausanne, 
Switzerland.11 Recruitment took place between April, 2003, 
and March, 2006, with 6186 individuals participating in 
the study. Of those invited to take part, 41% actually 
participated. Only white European individuals (ie, 
individuals for whom the four grandparents were white 
European) were included in the study. Participants 
provided a detailed health questionnaire and underwent 
a physical examination, including measurements of 
anthropometric variables. Participants donated blood 
after a 12-h fasting period for clinical chemistry and 
genetic analyses. Nuclear DNA was extracted from whole 
blood for whole genome scan analysis. Clinical chemistry 
assays were done by a clinical laboratory at the Centre 
Hospitalier Universitaire Vaudois on fresh blood samples 
on a Modular P apparatus (Roche Diagnostics, Basel, 
Switzerland) within 2 h of blood collection. Total 
cholesterol was assessed by CHOD-PAP (Roche 
Diagnostics, Basel, Switzerland; maximum inter-batch 
CV 1·6%; maximum intra-batch CV 1·7%) and HDL 
cholesterol by CHOD-PAP, polyethylene glycol, and 
cyclodextrin (maximum inter-batch CV 3·6%; maximum 
intra-batch CV 0·9%). LDL cholesterol was calculated 
with the Friedewald formula.8 The study was approved by 
the ethical committee of the faculty of medicine of 
Lausanne. The study was sponsored in part by 
GlaxoSmithKline, and all participants were duly informed 
about this sponsorship, and consented for the use of 
biological samples and data by GlaxoSmithKline and its 
subsidiaries.
The study population of the Genetic Epidemiology of 
Metabolic Syndrome (GEMS) study consisted of 
dyslipidaemic cases (age 20–65 years, n=1025) matched 
with normolipidaemic controls (n=1008) by sex and 
recruitment site.12 Detailed information on the GEMS 
study design, sampling frame, and recruitment procedures 
has been published.12 Serum triglycerides were measured 
enzymatically after hydrolysation to glycerol (Hitachi 704 
analyser; Hitachi, Tokyo, Japan). HDL cholesterol was 
measured after the precipitation of other lipoproteins with 
a heparin-manganese chloride mixture (Hitachi 704 
analyser). Dyslipidaemic participants were deﬁ ned as 
those with triglycerides above the 75th percentile and HDL 
cholesterol below the 25th percentile, on the basis of age, 
sex, and country-speciﬁ c distributions. Normolipidaemic 
controls (triglycerides <50th percentile, HDL cholesterol 
>50th percentile, and BMI >25 kg/m²), aged over 40 years 
were ascertained at the same time. Blood samples were 
collected after a 12-h fast and LDL-cholesterol concentration 
was calculated with the Friedewald formula.8 The study 
was sponsored in part by GlaxoSmithKline, and all 
participants were duly informed about this sponsorship, 
and consented for the use of biological samples and data 
by GlaxoSmithKline and its subsidiaries; the study was 
approved by the local ethics committees.
For conﬁ rmation of our results, we also included 
another subset from EPIC-Norfolk, consisting of up to 
3339 participants who did not overlap with the 
EPIC-Norfolk subcohort or obese set. These individuals 
were sequentially selected from those with DNA available 
for genotyping. We also used 1697 participants with DNA 
available for genotyping from the Ely study13 as another 
replication cohort—a population of white European men 
and women aged 35–79 years without diagnosed diabetes. 
This study is a population-based cohort study of the cause 
and pathogenesis of type 2 diabetes and related metabolic 
disorders in the UK. The Cambridge research ethics 
committee approved the study. All participants gave 
informed consent.
Selected study characteristics of all study populations 
are provided in webtable 1.
Procedures
Participants were genotyped with the Aﬀ ymetrix 
GeneChip Human Mapping 500K array set (Santa Clara, 
CA, USA). To optimise data quality and statistical 
analyses, sample and single nucleotide polymorphism 
(SNP) quality control criteria and statistical analysis of 
LDL cholesterol were done within each study, independent 
of the other studies. For the initial genome-wide 
association screen, analyses were also done within study. 
Thus, the relevant linear regression analyses were 
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optimised on the basis of the speciﬁ c characteristics of 
the individual studies.
For the EPIC-Norfolk subcohort and the EPIC-Norfolk 
obese set, SNP genotyping was done at the Aﬀ ymetrix 
services laboratory (San Francisco, CA, USA). Genotypes 
were obtained by the BRLMM algorithm clustered by 
plate.14 2566 participants were genotyped in the 
EPIC-Norfolk subcohort and 1284 in the obese set. 
Individuals were excluded by use of the following sample 
quality control criteria: proportion of all genotypes called 
was less than 94%; heterozygosity was less than 23% or 
more than 30%; if there was more than 5·0% discordance 
in SNP pairs with r²=1 in HapMap; ethnic outliers; related 
individuals (>70% concordance with another sample); 
and duplicates (concordance with another DNA 
was >99%). These exclusions left 2417 participants in the 
subcohort and 1135 in the obese set. We then applied the 
following SNP quality control criteria. SNPs were 
dropped if the proportion of genotypes called was 90% or 
less, if they were not in Hardy-Weinberg equilibrium 
(p<1×10¯⁶), and if they had a minor allele frequency 
(MAF) of 5% or less. We also restricted this analysis to 
autosomal SNPs. Therefore, there were 344 837 SNPs 
analysed in this genome-wide association scan for the 
EPIC-Norfolk subcohort. We also used the same subset 
of SNPs for analysis of the obese set. After sample and 
SNP quality control, 2269 individuals in the ﬁ rst 
subcohort and 1009 of those in the obese set had a 
measure of LDL cholesterol. LDL-cholesterol 
concentrations showed a near normal distribution in 
both studies. We therefore used untransformed LDL-
cholesterol data. Linear regression analysis was used to 
assess the association between each SNP and 
LDL-cholesterol concentration with an additive (per 
allele) model (1 df) by use of PLINK version 1.0. No 
covariables were included in these analyses.
For the 1958 British birth cohort, genotypes were 
measured with the Aﬀ ymetrix GeneChip 500K array and 
processed by the CHIAMO algorithm.10 After sample 
quality control checks for contamination, non-white 
European identity, overall heterozygosity, relatedness, 
low proportion of called genotypes, and evidence of 
non-white European ancestry, 1480 individuals were 
available with genome-wide association data. SNPs were 
excluded from the analysis because of missing data, 
departures from Hardy-Weinberg equilibrium and other 
metrics.10 These exclusions left 461 986 SNPs for analysis. 
1375 participants had data for LDL-cholesterol 
concentrations. Linear regression models were used to 
test the additive (per allele) eﬀ ect of the minor allele at 
each locus on untransformed LDL-cholesterol 
concentrations. Covariables included in this analysis 
included sex and study-speciﬁ c factors. Statistical analysis 
of the measured SNPs was done with Stata version 8.1.
For the CoLaus study, genotyping was done with 
Aﬀ ymetrix GeneChip Human Mapping 500K array set 
according to the Aﬀ ymetrix protocol. Genotypes were 
obtained with the BRLMM algorithm. Participants were 
removed from the analysis on the basis of the following 
sample quality control criteria: any participant whose sex 
was inconsistent with genetic data from X-linked SNPs; 
the proportion of genotypes called was less than 90%; 
having inconsistent genotypes when compared with 
duplicate samples. 5636 participants remained after 
sample quality control exclusions. We then applied SNP 
exclusions with the following criteria: SNPs that were 
monomorphic among all samples; SNPs with genotypes 
on less than 95% participants; SNPs that were out of 
Hardy-Weinberg equilibrium (p<1·0×10–⁷). After these 
quality control procedures, 370 697 SNPs remained for 
analysis. 5367 participants had a measure of LDL 
cholesterol. LDL-cholesterol concentrations showed 
some evidence of a non-normal distribution. Therefore, 
all regression analyses were done on natural 
log-transformed LDL-cholesterol concentrations, which 
showed a near normal distribution. We used linear 
regression analysis with an additive model adjusted for 
age, sex, and geographic origin. Analyses were done with 
PLINK version 1.0.
For the GEMS study, genotyping was done with the 
Aﬀ ymetrix GeneChip Human Mapping 500K array and 
the BRLMM calling algorithm. We excluded individuals 
on the basis of the same sample quality control criteria as 
for the CoLaus study. After sample quality control, 
1847 participants from the original sample remained. We 
then did a SNP quality assessment, excluding SNPs that 
were monomorphic, those that were out of 
Hardy-Weinberg equilibrium (p<1·0×10–⁷) or if the 
proportion of genotypes called for each SNP was less 
than 95%. After SNP quality control, 359 052 SNPs were 
available for analysis. 1665 participants had a measure of 
LDL cholesterol. Again, LDL-cholesterol concentrations 
seemed to have a non-normal distribution. We therefore 
did linear regression analysis with natural log-transformed 
LDL-cholesterol data and an additive model with 
adjustment for age, sex, study site, and dyslipidaemia 
status. Analyses were done with PLINK version 1.0.
To provide additional support for association signals, 
we examined data from the three of the ﬁ ve studies with 
a separate genotyping platform and SNP array. 
Participants from the EPIC-Norfolk subcohort and the 
EPIC-Norfolk obese set were also genotyped with the 
Inﬁ nium HumanHap300 SNP chip (Illumina, San 
Diego, CA, USA), containing 317 503 tagging SNPs 
derived from phase I of the International HapMap 
project. Of the SNPs assayed on these chips, we excluded 
SNPs if the proportion genotyped was 90% or less, if the 
MAF was 5% or less, and if the genotype distribution was 
out of Hardy-Weinberg equilibrium (p<1·0×10–⁶). 
Participants from the 1958 British birth cohort were 
genotyped with the Inﬁ nium HumanHap550 SNP chip 
(Illumina). Details of the sample and SNP quality control 
criteria have been published elsewhere.15 We did 
within-study analyses with an approach identical to the 
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analyses of Aﬀ ymetrix data. All Illumina genotyping was 
done at the Wellcome Trust Sanger Institute (Hinxton, 
Cambridgeshire, UK).
The EPIC-Norfolk replication set and the Ely study 
were genotyped with custom TaqMan SNP assays 
(Applied Biosystems, Warrington, UK) at Strangeways 
research laboratory (University of Cambridge, 
Cambridge, UK).
Statistical analysis
To increase statistical precision in the initial genome-wide 
association analysis with Aﬀ ymetrix data, we 
meta-analysed summary data from each of the ﬁ ve 
studies by use of a ﬁ xed eﬀ ects model and inverse-variance 
weighted averages of β coeﬃ  cients with Stata version 8.2. 
We therefore obtained a combined estimate of the overall 
β coeﬃ  cient and its SE. Between-study heterogeneity was 
assessed with the χ² test. To optimise data quality and 
statistical eﬃ  ciency, we only analysed SNPs that passed 
sample and SNP quality control criteria in each of the 
ﬁ ve studies and that had a measure of association 
(β coeﬃ  cient and SE) in all ﬁ ve studies.
We attempted to reduce the eﬀ ect of population 
stratiﬁ cation (confounding) by use of appropriate 
epidemiological design and statistical analysis, with 
ethnically homogeneous populations within each study. 
This approach also included adjusting for possible 
population stratiﬁ cation within study by use of geo-
graphical covariables, where appropriate. In the same 
context, all analyses were done conditioning on study. 
For each study, we also used quantile-quantile plots of 
the observed and expected distributions of p values to 
assess whether there was any evidence of distortion of 
the observed distribution from the null (data not shown). 
We also calculated an inﬂ ation factor (λ) for each study,16 
which was estimated from the mean of the χ² tests 
generated on all SNPs that were tested. On the basis of 
data for the 293 461 tested SNPs included in the 
meta-analysis, the distribution of the test statistics closely 
followed the null distribution for each study. Accordingly, 
the inﬂ ation factor was close to 1 for each study 
(webtable 2), suggesting that the observed associations 
are unlikely to be the result of population stratiﬁ cation or 
other artefacts. We also used this approach to calculate 
an inﬂ ation factor for the combined data. Dividing the 
χ² statistics for SNPs reaching genome-wide statistical 
association by this inﬂ ation factor did not alter the 
interpretation of these ﬁ ndings (data not shown).
Meta-analysis of data from Illumina assays was done in 
much the same way as for Aﬀ ymetrix data. 
Quantile-quantile plots of association within study 
indicated that the data followed the null distribution. By 
use of the method of genomic control, we again found 
that the inﬂ ation factor was close to 1 for each study 
(webtable 2), suggesting that the observed associations 
are unlikely to be the result of population stratiﬁ cation.
We used pairwise correlation (r²) to assess the extent of 
linkage disequilibrium between co-located SNPs. On the 
basis of linear regression analyses, we then used 
likelihood ratio tests to assess whether statistically 
associated SNPs independently contributed to the 
variation in LDL-cholesterol concentrations and to 
determine the source of any association signal. For these 
analyses, individual participant data were available for 
only four studies (no data were available for the 1958 
British birth cohort). Speciﬁ cally, we compared the log 
likelihood of a nested model (2 df) with that of the full 
model (3 df) by consecutively adding extra SNPs (in a log 
Chromosome Position* Nearest locus Minor 
allele†
Frequency† Pooled β coeﬃ  cient 
(SE)‡
Combined 
p value
p value for 
heterogeneity
Rank
rs4420638 19 50114786 APOC1 G 0·18 0·06 (0·01) 1·2×10²⁰ 2·8×10⁹ 1
rs599839 1 109623689 PSRC1 G 0·21 –0·05 (0·01) 1·7×10¹⁵ 2·0×10⁵ 2
rs4970834 1 109616403 CELSR2 T 0·19 –0·04 (0·01) 3·0×10¹¹ 0·01 3
rs562338 2 21141826 APOB T 0·20 –0·04 (0·01) 1·4×10⁹ 3·1×10⁵ 4
rs7575840 2 21126995 APOB T 0·34 0·03 (0·01) 1·9×10⁹ 4·8×10⁴ 5
rs478442 2 21252721 APOB G 0·21 –0·03 (0·01) 8·1×10⁹ 4·4×10⁴ 6
rs4591370 2 21237247 APOB A 0·21 –0·03 (0·01) 8·2×10⁹ 2·5×10⁴ 7
rs4560142 2 21237222 APOB C 0·21 –0·03 (0·01) 8·3×10⁹ 4·4×10⁴ 8
rs576203 2 21247128 APOB A 0·21 –0·03 (0·01) 9·0×10⁹ 3·0×10⁴ 9
rs506585 2 21250687 APOB G 0·21 –0·03 (0·01) 1·0×10⁸ 3·9×10⁴ 10
rs488507 2 21247194 APOB G 0·22 –0·03 (0·01) 2·0×10⁸ 1·3×10³ 11
rs538928 2 21242524 APOB A 0·20 –0·03 (0·01) 2·7×10⁸ 6·8×10⁴ 12
rs10402271 19 50021054 BCAM G 0·33 0·03 (0·01) 4·1×10⁸ 0·02 13
rs693 2 21085700 APOB C 0·47 –0·03 (0·01) 4·4×10⁸ 0·02 14
*On basis of NCBI Build 36·2. †On basis of EPIC-Norfolk sub-cohort: minor allele corresponds to forward strand of NCBI Build 36·2. ‡β coeﬃ  cients represent the change in 
LDL-cholesterol concentration per additional minor allele.
Table 1: Statistical associations (p<1·0×10–7) between Aﬀ ymetrix SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis 
of ﬁ ve study populations consisting of up to 11 685 participants
See Online for webtable 2
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additive form) to a model containing the SNP with the 
strongest statistical signal from the genome-wide screen 
(general inheritance [2 df ] form). We also did a reciprocal 
analysis, adding the SNP with the strongest statistical 
signal from the genome-wide screen (1 df form) to a 
model containing other SNPs showing statistical 
association (2 df form). All analyses were done with Stata 
version 8.2.
We then generated a linkage disequilibrium plot with 
Haploview.17 Linkage disequilibrium blocks are 
delineated by black lines and deﬁ ned with the method of 
Gabriel and colleagues.18 To provide a more detailed 
assessment of chromosomal regions showing statistical 
association, and to further reﬁ ne the location of any 
association signal, we imputed SNPs on the basis of 
HapMap phase II data with IMPUTE.19 We used 
information on SNP genotypes in our studies and 
HapMap II data to statistically predict all SNP genotypes 
in a chromosomal region for all individuals. For these 
imputed data, association analysis was done with 
SNPTEST (with the full posterior probability genotype 
distribution) for the imputed genotypes and LDL-
cholesterol data for each study separately (adding in 
relevant covariables). β coeﬃ  cients were combined as 
before. Only SNPs with a MAF of 1% or more and with a 
posterior-probability score more than 0·90 were 
considered for these imputed association analyses.10 
Imputed data were not available for the GEMS study.
To increase comparability between studies, we 
reanalysed data from CoLaus and GEMS where we had 
individual participant data with untransformed 
LDL-cholesterol data and with no covariable adjustment. 
We then did a meta-analysis of all studies, including the 
replication studies and untransformed data from CoLaus 
and GEMS. As before, we obtained β coeﬃ  cients and SE 
from each study and used a ﬁ xed eﬀ ects model and 
inverse-variance weighting to obtain a combined 
estimate of the overall β coeﬃ  cient and its SE. 
Heterogeneity between studies was assessed with 
χ² tests. Finally, we did a pooled analysis (conditioning 
on study) of all studies in which we had individual 
participant data. This analysis provided an estimate of 
the magnitude of the relation between these SNPs and 
LDL-cholesterol concentrations in a comparable way, 
and also provided a measure of the variation in circulating 
LDL-cholesterol concentrations explained by each SNP. 
We also used multivariable linear regression analysis to 
examine whether age and sex aﬀ ected these associations. 
By use of these pooled data, we also contextualised our 
results as a proportion of a SD change in LDL-cholesterol 
concentrations. All analyses were done with Stata 
version 8.2. For a downloadable ﬁ le of all results, 
including additional analyses, see http://www.srl.cam.
ac.uk/gecd/.
Role of the funding source
This study was funded by UK Medical Research Council, 
Wellcome Trust, British Heart Foundation, and 
GlaxoSmithKline. Employees of GlaxoSmithKline 
contributed to the study design, data analysis, data 
interpretation, and writing of the report. Other sponsors 
of the study had no role in data collection, the study 
design, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
the data and ﬁ nal responsibility for the decision to submit 
for publication.
Results
Data for 293 461 autosomal SNPs identiﬁ ed with 
Aﬀ ymetrix were available for analysis in up to 
11 685 individuals from ﬁ ve studies. 14 SNPs were 
statistically associated with circulating LDL-cholesterol 
concentrations at the genome-wide level (p<1·0×10–⁷; 
table 1). The 14 SNPs showed directionally consistent 
signals in all ﬁ ve studies (webtable 3). These SNPs were 
broadly conﬁ ned to three distinct genomic regions 
(table 1), two of which were close to known loci involved 
in LDL-cholesterol metabolism (including those 
encompassing the APOB and APOE genes).2,20,21 Notably, 
two SNPs—rs599839 (p=1·7×10–¹⁵) and rs4970834 
(p=3·0×10–¹¹)—showed evidence for statistical association 
and were both located at chromosomal region 1p13.3. For 
Chromosome Position* Nearest locus Minor 
allele†
Frequency† Pooled 
β coeﬃ  cient (SE)‡
Combined 
p value
p value for 
heterogeneity
Rank
rs2075650 19 50087459 TOMM40 G 0·13 0·23 (0·03) 7·1×10¹⁴ 0·15 1
rs4803750 19 49939467 BCL3 G 0·07 –0·28 (0·04) 2·4×10¹¹ 0·14 2
rs646776 1 109620053 CELSR2 G 0·21 –0·16 (0·03) 4·3×10⁹ 0·70 3
rs1713222 2 21124828 APOB T 0·16 –0·17 (0·03) 1·0×10⁸ 0·56 4
rs2228671 19 11071912 LDLR T 0·12 –0·18 (0·03) 1·1×10⁸ 0·50 5
rs11668477 19 11056030 LDLR G 0·20 –0·15 (0·03) 1·5×10⁸ 0·95 6
rs4605275 19 50030333 BCAM T 0·31 –0·13 (0·02) 4·7×10⁸ 0·74 7
*On basis of NCBI Build 36·2. †On basis of EPIC-Norfolk subcohort; minor allele corresponds to forward strand of NCBI Build 36·2. ‡β coeﬃ  cients represent the change in 
LDL-cholesterol concentration per additional minor allele.
Table 2: Statistical associations (p<1·0×10–7) between Illumina SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of 
three UK study populations consisting of up to 4337 participants
See Online for webtable 3
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Figure 1: Linkage 
disequilibrium plot
(A) Plot of 98 kb genomic 
region aligned with association 
signals for imputed SNPs. 
Positions of genes, SNPs 
genotyped in HapMap, and 
linkage disequilibrium among 
SNPs (r² is shown). r² values 
of 1·0 are depicted by red 
diamonds, intermediate 
r² values are represented in 
pink, and r² values of 0 as 
white. Aligned underneath the 
linkage disequilibrium plot is a 
graph showing the association 
signal for each of the 71 SNPs 
which could be imputed from 
our data. The plot was 
generated with HapMap 
(release 22/phase II Apr 07, 
NCBI B36 assembly, dbSNP 
build 126, [CEPH Utah trios], 
chr1 co-ordinates 
109541887-109640441). This 
plot illustrates that the 
strongest association signals 
are localised to a 14 kb region 
shown in detail in (B). Imputed 
SNPs that were statistically 
associated with circulating 
concentrations of LDL 
cholesterol at the 
genome-wide level 
(p<1·0×10⁷) are boxed.
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these SNPs, there was no material evidence for 
heterogeneity between studies after adjustment for 
multiple testing (table 1).
Data for 290 140 SNPs identiﬁ ed with Illumina were 
available for analysis across the three studies that were 
assessed with these chips. For these analyses, we had up 
to 4337 participants with a measure of LDL-cholesterol 
concentration. Seven SNPs were statistically associated 
with circulating LDL-cholesterol concentrations at the 
genome-wide level (p<1·0×10–⁷; table 2 and webtable 4). 
Six of these SNPs were located in genomic regions 
previously linked to LDL-cholesterol metabolism. 
However, we also found another SNP located at 
chromosomal region 1p13.3 (rs646776; p=4·3×10–⁹).
Linkage disequilibrium plots of the three SNPs located 
at 1p13.3 implicated a region spanning several genes 
(webﬁ gure). The strongest statistically associated SNP 
(rs599839) lay 3´  to the CELSR2 and PSRC1 genes (the 
two genes are in a tail-to-tail orientation) in a 98 kb region 
of fragmented linkage disequilibrium. This region 
contained several recombination hotspots and was 
situated between two blocks of strong linkage 
disequilibrium (webﬁ gure). SNP rs4970834 also lay in 
this region and in our studies was correlated with SNP 
rs599839 (r²=0·79; webtable 5). SNP rs646776 was also 
colocalised with these SNPs and was highly correlated 
(r²=0·94) with SNP rs599839 (webtable 5). For all three 
SNPs, the minor allele, with a frequency of around 19–21%, 
was associated with lower LDL-cholesterol concentrations 
(table 1 and table 2).
Likelihood ratio tests of up to 10 310 participants 
showed that, for the Aﬀ ymetrix SNPs, assuming that 
SNP rs599839 was the causal variant or in near complete 
linkage disequilibrium with the causal variant(s), 
inclusion of SNP rs599839 as a covariable explained the 
other observed SNP associations in this region 
(webtable 6). In an exploratory and equivalent analysis on 
a small subset of samples with both Aﬀ ymetrix and 
Illumina SNP data (up to 3007 participants), we found 
that both SNPs rs599839 and rs646776, which are highly 
correlated, equally explained the association signals in 
this region (webtable 6). Thus, when conditioning on 
SNP rs599389, our results indicated that the three 
statistically associated SNPs might be characterising 
identical genetic variant(s) in this region.
Imputation of all SNPs with a MAF of 1% or more from 
our Aﬀ ymetrix array and HapMap II data for this 98 kb 
region for 9988 participants allowed us to assess whether 
additional association signals might be present in this 
region. On the basis of these imputed data, the strongest 
evidence for association was found for SNP rs646776 
(p=3·0×10–¹⁴; ﬁ gure 1 and table 3). Indeed, within this 
98 kb region, the strongest association signals from both 
imputed and genotyped data were localised to a 14 kb 
region containing a group of seven highly correlated 
SNPs that included the 3´  untranslated region (UTR) of 
the CELSR2 gene (ﬁ gure 1 and table 3). By use of data 
from HapMap, we found that SNPs rs599839 and 
rs646776 tag six of these seven SNPs with an r² 
between 0·96 and 1·00. However, in view of the strong 
linkage disequilibrium, the speciﬁ c source of the 
association signal is unlikely to be reliably diﬀ erentiated 
between these SNPs in our data.
To validate associations found in our genome-wide 
association screens and imputational analysis, we 
genotyped rs599839 and rs646776 in the two replication 
cohorts (webtable 7). There was again  evidence of 
statistical association in each of these studies (webtable 7), 
thus corroborating our imputed results.
Lastly, we conducted a meta-analysis and pooled 
analysis of all available studies by use of a comparable 
analytical approach. Meta-analysis of data for up to 
16 571 participants showed evidence for statistical 
association for SNP rs599839 with LDL-cholesterol 
concentrations (p=1·2×10–³³; webtable 7). On the basis of 
data for up to 9282 participants, we found evidence for 
statistical association for SNP rs646776 with 
LDL-cholesterol concentrations (p=4·8×10–²⁰). These 
See Online for webtables 4, 5, 6, 
and 7
See Online for webﬁ gure
Genomic position* Position relative to 
CELSR2 gene
Minor 
allele†
Frequency† Pooled 
β-coeﬃ  cient (SE)
Combined 
p value
p value for 
heterogeneity
rs646776 109620053 3’ (intergenic) G 0·21 –0·13 (0·02) 3·0×10–14 0·16
rs629301 109619829 3’ UTR C 0·21 –0·13 (0·02) 3·1×10–14 0·15
rs12740374 109619113 3’ UTR T 0·21 –0·13 (0·02) 3·2×10–14 0·15
rs660240 109619361 3’ UTR A 0·21 –0·14 (0·02) 3·8×10–14 0·17
rs602633 109623034 3’ intergenic A 0·22 –0·13 (0·02) 5·7×10–14 0·18
rs599839 109623689 3’ (intergenic) G 0·19 –0·12 (0·02) 7·8×10–11 0·45
rs611917 109616775 Intronic C 0·28 –0·11 (0·02) 1·5×10–10 0·05
rs4970834 109616403 Intronic T 0·17 –0·12 (0·02) 6·7×10–10 0·41
rs6657811 109608806 Intronic T 0·12 –0·13 (0·02) 2·0×10–8 0·04
UTR=untranslated region. *On basis of NCBI Build 36·2. †On basis of EPIC-Norfolk subcohort; minor allele corresponds to forward strand of NCBI Build 36·2. ‡β coeﬃ  cients 
represent the change in LDL-cholesterol concentration per additional minor allele.
Table 3: Imputed SNPs showing genome-wide statistical association (p<1·0x10–7) with circulating concentrations of LDL cholesterol; meta-analysis of 
four study populations consisting of up to 9988 participants
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associations were directionally consistent across all 
studies (ﬁ gure 2), with no heterogeneity between studies 
(p=0·43 for SNP rs599839 and p=0·88 for rs646776).
A pooled analysis of all studies in which we had 
individual participant data, which consisted of 
15 196 individuals for SNP rs599839 and 7952 individuals 
for SNP rs646776, suggested that SNPs rs599839 and 
rs646776 both explained around 1% of the variation in 
circulating LDL-cholesterol concentrations and were 
associated with about 15% of an SD change in 
LDL-cholesterol concentrations per allele (ﬁ gure 2). 
Further adjustment for age and sex did not alter these 
ﬁ ndings (data not shown).
Discussion
Our data provide evidence for a locus for LDL cholesterol 
at chromosome region 1p13.3. This locus has not 
previously been related to lipid metabolism.4,20 These 
results could provide insight into the biological 
mechanisms that underlie the regulation of 
LDL-cholesterol concentrations and might help to 
identify new therapeutic targets for cardiovascular 
disease. The magnitude of the association was consistent 
across the studies we examined, and showed independent 
evidence for statistical association in each study.
Examination of the publicly available Aﬀ ymetrix 500K 
results from the Diabetes Genetics Initiative genome-wide 
association scan of LDL-cholesterol concentrations22 
suggests that rs599839 and rs4970834—the two most 
strongly associated SNPs from our Aﬀ ymetrix array—
also showed clear evidence for statistical association 
(p=9·0×10–⁸ and p=1·2×10–⁴, respectively) with 
LDL-cholesterol concentrations, providing independent 
conﬁ rmation of our ﬁ ndings.
Our results are unlikely to be artifacts. We used several 
genotyping technologies, independent replication, and 
stringent statistical criteria to deﬁ ne our associations.23 
The consistency of the association across heterogeneous 
populations also argues against a false positive 
association. By contrast, random error in the 
measurement of LDL-cholesterol concentrations might 
have lead to an underestimation of the magnitude of the 
association between these genetic variants and LDL-
cholesterol concentrations. However, it is likely that our 
study does not have the statistical power to detect other 
novel genetic determinants with smaller eﬀ ects on LDL-
cholesterol concentrations. Even larger scale studies will 
be required to detect these associations. Consistent with 
a causal link between LDL cholesterol and risk of coronary 
artery disease, the locus that we identiﬁ ed has also shown 
statistical association with risk of coronary heart disease 
in other genome-wide association studies.24 This 
association is directionally consistent with our data. 
Speciﬁ cally, our data show that minor allele carriers of 
these genetic variants, who made up around 20% of our 
populations, have lower circulating LDL-cholesterol 
concentrations. In keeping with this ﬁ nding, a 
genome-wide association of coronary heart disease found 
that individuals with these alleles have a lower risk of 
developing coronary artery disease than do individuals 
who are homozygous for the major allele.24 In this context, 
our study also shows that, in addition to discovering new 
genetic determinants of quantitative traits, genome-wide 
association studies of quantitative risk factors can provide 
a research framework to determine the mechanism 
underlying association signals for relevant disease 
susceptibility genes.
Genetic variants at this locus explained around 1% of 
the variation in LDL-cholesterol concentrations, and were 
associated with about 15% of an SD change in 
LDL-cholesterol concentrations per allele, on the basis of 
a SD of around 1 mmol/L. With caveats, these variants 
might therefore have use as genetic tools for causal 
inference in Mendelian randomisation studies of 
cardiovascular disease.25
Up to now, genetic variation at the apolipoprotein E 
and B genes, the LDL receptor gene, and variation at the 
gene encoding proprotein convertase subtilisin/kexin 
type 9 (PCSK9) has been consistently shown to aﬀ ect 
LDL-cholesterol concentrations.2,20,21,26–28 Mutations in 
these genes are also causes of familial hypercholes-
terolaemia.2,27,29 Our data indicate that association signals 
between genetic variants at the 1p13.3 locus and 
LDL-cholesterol concentrations might be localised to the 
3´  UTR of the CELSR2 gene—the cadherin EGF LAG 
seven-pass G-type receptor 2. Further genetic 
epidemiological studies could help clarify the source of 
β coeﬃcient (per allele change in LDL cholesterol [mmol/L])
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Figure 2: Association between SNPs at the 1p13.3 locus and circulating concentrations of LDL cholesterol
For individual studies β coeﬃ  cients are depicted by black boxes and spanned by 95% CI. Diamonds represent 
overall β coeﬃ  cients for each SNP and the width of the diamonds delineate their 95% CI. Corresponding values for 
each independent study and for the overall estimate are given to the right of the plot.
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the association signal or the causal variant(s). However, 
because of the strong correlation between statistically 
associated SNPs at this gene in European populations, 
studies of populations with greater genetic diversity 
might be required to help resolve these association 
signals. The biological role of the CELSR2 gene is 
unknown. Functional studies and examination of genetic 
mutations in this region might help clarify the role of 
proteins encoded by this genomic region in lipid 
metabolism and disorders, including familial 
hypercholesterolaemia.
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